Table 5.
Efficiency of cefaclor in patients with in vitro resistance to specific antibiotics including levofloxacin and cefazolin
| Antimicrobial agent | n | Success | Pathogen | n | Success |
|---|---|---|---|---|---|
| Levofloxacin | 24 (10.3) | 24 (100) | Escherichia coli | 17 (70.8) | 17 (100) |
| Escherichia coli-ESBL | 1 (4.1) | 1 (100) | |||
| Cefazolin | 15 (6.4) | 14 (93.3) | Escherichia coli | 3 (20.0) | 3 (100) |
| Escherichia coli-ESBL | 3 (20.0) | 2 (66.6) | |||
| Levofloxacin and cefazolin | 15 (6.4) | 9 (60.0) | Escherichia coli | 1 (6.7) | 1 (100) |
| Escherichia coli-ESBL | 14 (93.3) | 8 (57.1) |
Unless otherwise stated, number of patients with percentages in parentheses
ESBL Extended spectrum beta-lactamase